Cervical Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV031 MIFTS: 55	Cervical Adenocarcinoma Categories: Reproductive diseases, Rare diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma ¹² ⁵⁹ ⁵⁵ ¹⁵ ⁷³

Adenocarcinoma of the Uterine Cervix ¹²

Adenocarcinoma of the Cervix Uteri ⁵⁹

Adenocarcinoma Cervix Uteri ¹²

Adenocarcinoma of Cervix ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Endocervix

Malignant neoplasm: Exocervix

Malignant neoplasm: Overlapping lesion of cervix uteri

Orphanet: ⁵⁹

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:3702

NCIt ⁵⁰ C4029

SNOMED-CT ⁶⁸ 154522004 254887002 269596006

Orphanet ⁵⁹ ORPHA213772

UMLS via Orphanet ⁷⁴ C0279672

ICD10 via Orphanet ³⁴ C53.0 C53.1 C53.8

UMLS ⁷³ C0279672

Sources

Summaries for Cervical Adenocarcinoma

Disease Ontology : ¹² A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to glassy cell carcinoma of the cervix and adenosquamous carcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Gardasil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are cellular and digestive/alimentary

Sources

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)

#	Related Disease	Score	Top Affiliating Genes
1	glassy cell carcinoma of the cervix	32.4	ERBB2 ESR1
2	adenosquamous carcinoma	30.6	EGFR KRT7 TP53
3	adenocarcinoma	30.5	CDKN2A EGFR ERBB2 PTGS2 TP53
4	adenocarcinoma in situ	30.4	CDKN1A CDKN2A CDX2 KRT20 KRT7
5	female reproductive endometrioid cancer	30.4	KRT7 TP53
6	cervical squamous cell carcinoma	30.4	CDKN2A RASSF1 TP53
7	suppressor of tumorigenicity 3	30.2	CDKN1A CDKN2A TP53
8	small cell carcinoma	29.6	EGFR KRT20 KRT7 TP53
9	ovarian cancer 1	29.5	ERBB2 KRT7 TP53
10	renal cell carcinoma, nonpapillary	29.4	EGFR KRT20 KRT7 RASSF1
11	squamous cell carcinoma	29.4	CDKN2A EGFR ERBB2 PTGS2 TP53
12	nasopharyngeal carcinoma	29.4	CDKN2A EGFR RASSF1 TP53
13	vulval paget's disease	29.3	CDKN2A ERBB2 KRT20 KRT7
14	papilloma	29.1	CDKN1A CDKN2A KRT20 KRT7 TP53
15	endometrial adenocarcinoma	27.9	CDKN2A EGFR ERBB2 ESR1 KRT7 TP53
16	lung cancer	26.7	CDKN1A CDKN2A EGFR ERBB2 KRT7 PTGS2
17	early invasive cervical adenocarcinoma	12.1
18	inverted transitional papilloma	10.9	CDKN2A KRT7
19	ovary neuroendocrine neoplasm	10.9	CDX2 KRT7
20	brain stem astrocytic neoplasm	10.9	CDKN2A TP53
21	cystic basal cell carcinoma	10.9	KRT20 KRT7
22	anus adenocarcinoma	10.8	CDX2 KRT7
23	seminal vesicle adenocarcinoma	10.8	KRT20 KRT7
24	transverse colon cancer	10.8	KRT20 KRT7
25	ovarian large-cell neuroendocrine carcinoma	10.8	KRT20 KRT7
26	bowenoid papulosis	10.8	CDKN2A PTGS2
27	protoplasmic astrocytoma	10.8	PTGS2 TP53
28	eyelid neoplasm	10.8	KRT20 KRT7
29	cervicitis	10.8
30	malignant syringoma	10.8	KRT20 KRT7
31	krukenberg carcinoma	10.8	KRT20 KRT7
32	large intestine adenocarcinoma	10.8	KRT20 KRT7
33	linitis plastica	10.8	KRT20 KRT7
34	lung acinar adenocarcinoma	10.8	KRT20 KRT7
35	small cell carcinoma of the bladder	10.8	KRT20 KRT7
36	malignant peritoneal mesothelioma	10.8	CDKN2A EGFR
37	malignant spiradenoma	10.8	KRT7 TP53
38	bile reflux	10.8	CDX2 PTGS2
39	benign breast adenomyoepithelioma	10.8	EGFR KRT7
40	keratinizing squamous cell carcinoma	10.8	CDKN2A TP53
41	adenoid squamous cell carcinoma	10.7	KRT20 KRT7
42	brain ependymoma	10.7	EGFR TP53
43	vestibular gland benign neoplasm	10.7	ESR1 TP53
44	bladder papillary transitional cell neoplasm	10.7	KRT20 TP53
45	endometrial clear cell adenocarcinoma	10.7	ESR1 TP53
46	bartholin's gland adenoma	10.7	ESR1 TP53
47	urinary tract papillary transitional cell benign neoplasm	10.7	KRT20 TP53
48	anaplastic oligodendroglioma	10.7	CDKN2A EGFR
49	epithelial predominant wilms' tumor	10.7	CDX2 KRT7
50	spitz nevus	10.7	CDKN2A TP53

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:

Sources

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

⁴⁶ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.3	TP53 RASSF1 PTGS2 ESR1 KRT7 ERBB2
2	digestive/alimentary	MP:0005381	10.25	TP53 RASSF1 PTGS2 ESR1 ERBB2 LAMC2
3	homeostasis/metabolism	MP:0005376	10.25	TP53 PTGS2 VIL1 RASSF1 ERBB2 ESR1
4	cardiovascular system	MP:0005385	10.22	TP53 RASSF1 ERBB2 PTGS2 ESR1 EGFR
5	endocrine/exocrine gland	MP:0005379	10.18	TP53 RASSF1 PTGS2 ESR1 ERBB2 EGFR
6	immune system	MP:0005387	10.15	TP53 PTGS2 RASSF1 LAMC2 EGFR ESR1
7	embryo	MP:0005380	10.14	TP53 PTGS2 ESR1 ERBB2 EGFR CDKN2A
8	integument	MP:0010771	10.08	TP53 LAMC2 PTGS2 ESR1 ERBB2 EGFR
9	neoplasm	MP:0002006	10.02	TP53 RASSF1 PTGS2 ESR1 ERBB2 EGFR
10	limbs/digits/tail	MP:0005371	10	TP53 LAMC2 ESR1 ERBB2 EGFR CDKN1A
11	liver/biliary system	MP:0005370	9.98	TP53 RASSF1 PTGS2 ESR1 EGFR CDKN2A
12	muscle	MP:0005369	9.95	TP53 PTGS2 ERBB2 EGFR ESR1 CDKN1A
13	normal	MP:0002873	9.92	TP53 PTGS2 VIL1 RASSF1 ERBB2 ESR1
14	renal/urinary system	MP:0005367	9.8	TP53 LAMC2 PTGS2 ESR1 KRT7 EGFR
15	reproductive system	MP:0005389	9.76	TP53 PTGS2 ERBB2 EGFR ESR1 CDKN1A
16	respiratory system	MP:0005388	9.56	TP53 PTGS2 ESR1 ERBB2 LAMC2 EGFR
17	skeleton	MP:0005390	9.28	TP53 PTGS2 ESR1 ERBB2 LAMC2 EGFR

Sources

Drugs & Therapeutics for Cervical Adenocarcinoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Vaccines

Phase 4,Phase 3,Phase 2

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Topotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

119413-54-6, 123948-87-8

60700

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1

95058-81-4

60750

Vinblastine

Approved

Phase 3

865-21-4

13342 241903

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

60780 44424639

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Fluorouracil

Approved

Phase 3,Phase 1,Phase 2

51-21-8

3385

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

126941

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2

58-05-9

143 6006

Tirapazamine

Investigational

Phase 3,Phase 1

27314-97-2

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antiviral Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2

Angiogenesis Modulating Agents

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Alkylating Agents

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2

Antibiotics, Antitubercular

Phase 3,Phase 2

Antineoplastic Agents, Alkylating

Phase 3,Phase 2

Antirheumatic Agents

Phase 3,Phase 1,Phase 2

Dermatologic Agents

Phase 3

Folic Acid Antagonists

Phase 3,Phase 2

Isophosphamide mustard

Phase 3

Mitomycins

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Vitamin B Complex

Phase 3,Phase 2

Folate

Nutraceutical

Phase 3,Phase 2

Vitamin B9

Nutraceutical

Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 93)

#	Name	Status	NCT ID	Phase	Drugs
1	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Completed	NCT01544478	Phase 4
2	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
3	Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)	Completed	NCT00834106	Phase 3
4	Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
5	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6	Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer	Completed	NCT00003209	Phase 3	cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7	Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00003945	Phase 3	cisplatin;topotecan hydrochloride
8	Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia	Completed	NCT00017004	Phase 3	Cisplatin
9	Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix	Completed	NCT00003078	Phase 3	cisplatin;fluorouracil
10	Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer	Recruiting	NCT02853604	Phase 3	ADXS11-001;Placebo
11	Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery	Recruiting	NCT01101451	Phase 3	Cisplatin
12	Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy	Recruiting	NCT00980954	Phase 3	carboplatin;cisplatin;paclitaxel
13	Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer	Active, not recruiting	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
14	Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer	Active, not recruiting	NCT00039338	Phase 3	cisplatin
15	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
16	A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)	Not yet recruiting	NCT03493542	Phase 3
17	Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix	Terminated	NCT00054067	Phase 3	cisplatin
18	Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
19	Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer	Terminated	NCT00085631	Phase 3	cisplatin
20	Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer	Unknown status	NCT00008112	Phase 2	cisplatin
21	Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer	Unknown status	NCT01158248	Phase 2	cisplatin
22	Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer	Unknown status	NCT00462397	Phase 2	carboplatin;cisplatin;paclitaxel
23	Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application	Completed	NCT01639625	Phase 2	CIGB300
24	Ixabepilone to Treat Cervical Cancer	Completed	NCT00924066	Phase 2	Ixempra (Ixabepilone (BMS-247550) )
25	Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00039442	Phase 2	Capecitabine
26	Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer	Completed	NCT02562729	Phase 2
27	Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL	Completed	NCT01957878	Phase 2
28	Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery	Completed	NCT00389974	Phase 2	sunitinib malate
29	ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
30	Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
31	Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer	Completed	NCT00002562	Phase 2	paclitaxel
32	Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer	Completed	NCT00005999	Phase 2	arsenic trioxide
33	Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
34	Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer	Completed	NCT00005070	Phase 2	irofulven
35	Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix	Completed	NCT00003017	Phase 2
36	Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer	Completed	NCT00002916	Phase 2
37	Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix	Completed	NCT00003065	Phase 2	paclitaxel;topotecan hydrochloride
38	Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
39	Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery	Completed	NCT01026792	Phase 2	Temsirolimus
40	FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer	Completed	NCT00559377	Phase 2
41	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer	Completed	NCT00369122	Phase 2	Cisplatin
42	Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery	Completed	NCT01229930	Phase 2	carboplatin;cediranib maleate;paclitaxel
43	Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer	Completed	NCT00807079	Phase 1, Phase 2	carboplatin;topotecan hydrochloride
44	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer	Completed	NCT00957411	Phase 2	cisplatin
45	Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer	Completed	NCT00012012	Phase 1, Phase 2	Amifostine trihydrate;Cisplatin
46	Radiation Therapy in Treating Patients With Cervical Cancer	Completed	NCT00278304	Phase 2
47	Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer	Completed	NCT00101192	Phase 2	cisplatin
48	Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer	Completed	NCT01590017	Phase 2	cisplatin
49	Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer	Completed	NCT00276796	Phase 2	cisplatin;paclitaxel;topotecan hydrochloride
50	Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery	Completed	NCT00331760	Phase 2	cisplatin

Search NIH Clinical Center for Cervical Adenocarcinoma

Sources

Genetic Tests for Cervical Adenocarcinoma

Sources

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

⁴¹

Cervix, Lymph Node, Testes, Endothelial, Liver, Ovary, Colon

Sources

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 337)

#	Title	Authors	Year
1	Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. ( 29474242 )	Sar A....Duggan M.A.	2018
2	Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. ( 29144012 )	Ohya A....Kadoya M.	2018
3	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. ( 29750702 )	Turashvili G....Murali R.	2018
4	Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )	Okonogi N....Shozu M.	2018
5	miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-I^RI signaling pathway. ( 29531222 )	Fang F....Wang Z.	2018
6	Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )	Xu H.Y....Hua K.	2018
7	Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB. ( 29480826 )	Zhou J....Lou H.	2018
8	Concomitant endometrial and cervical adenocarcinoma: A case report and literature review. ( 29505548 )	Xu M....Huang L.	2018
9	MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. ( 29871972 )	Wang D....Li Q.	2018
10	The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. ( 29876746 )	Feng Y....Zhang Z.	2018
11	Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. ( 28331901 )	Deshmukh U....Azodi M.	2017
12	Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )	van der Horst J....de Kok I.M.	2017
13	Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. ( 28720447 )	Smith M.A....Canfell K.	2017
14	Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells. ( 29067110 )	Takiguchi E....Irahara M.	2017
15	Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. ( 29027399 )	Wu S.G....Zhou J.	2017
16	Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )	Munro A....Cohen P.A.	2017
17	Tumor-associated CD204<sup>+</sup>M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. ( 29274107 )	Kawachi A....Hiraoka N.	2017
18	Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. ( 28644686 )	Pirog E.C.	2017
19	Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells. ( 28249781 )	Zhang F....Wei Z.J.	2017
20	Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )	Yoshida H....Kato T.	2017
21	Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. ( 28631536 )	Hu J....Zhu L.	2017
22	Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. ( 28245508 )	EleutAcrio J....Silva A.M.	2017
23	Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )	Cohen P.A....Stoyles P.	2017
24	Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )	Nash S....Pemberton J.	2017
25	Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )	Jung E.J....Jeong D.H.	2017
26	Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma. ( 28186628 )	Han Y....Wu L.	2017
27	Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )	Jiang Y....Li L.	2017
28	Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. ( 27227411 )	Smelov V....Dillner J.	2016
29	Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )	Mancini S....Bucchi L.	2016
30	Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. ( 26847087 )	Akimoto T....Sawada N.	2016
31	The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. ( 27554015 )	Chen W....Qiao Y.	2016
32	Uterine cervical adenocarcinoma metastasizing concurrently to eutopic and ectopic ovaries: A case report. ( 27005982 )	Kiuchi K....Fukasawa I.	2016
33	Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )	Twu N.F....Lai C.H.	2016
34	Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. ( 27977543 )	Moukarzel L.A....Levinson K.	2016
35	Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. ( 27102248 )	Yang J....Cao D.	2016
36	Cervical Adenocarcinoma: Are We Screening and Treating Patients Appropriately? ( 27529155 )	Soares L.C....De Oliveira M.A.	2016
37	Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma. ( 27654088 )	Samuels S....Jordanova E.S.	2016
38	Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )	Carneiro V.C.	2016
39	Correlation between EGFR Expression and Radiosensitivity in Cervical Adenocarcinoma Cases. ( 27268625 )	Hernowo B.S....Wibisono F.	2016
40	Prevalence of HPV genotypes in cervical adenocarcinoma: a study in Greek women. ( 27569088 )	Chrysagi A....Pavlakis K.	2016
41	Case images: Cervical adenocarcinoma presenting with a terrible combination: a giant cardiac mass, cardiac tamponade and pulmonary embolism. ( 28045425 )	Keskin M....Ahmet A.	2016
42	Cytomorphology of Gastric-Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16-Positive Tumor Case. ( 27165398 )	Fulmer C.G....Holcomb K.	2016
43	Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and metaanalysis. ( 27133009 )	Chen J....Li K.	2016
44	Biology and treatment of cervical adenocarcinoma. ( 27198186 )	Takeuchi S.	2016
45	Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors. ( 27677664 )	Seki T....Okamoto A.	2016
46	Cervical adenocarcinoma with stromal micropapillary pattern. ( 26608235 )	Toyoda S....Ohbayashi C.	2016
47	FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. ( 25795131 )	Punt S....Jordanova E.S.	2015
48	Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB. ( 26495760 )	Mabuchi Y....Ino K.	2015
49	Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection. ( 26046000 )	Kong F....Jia Y.	2015
50	Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )	Munro A....Cohen P.	2015

Sources

Genes for Cervical Adenocarcinoma

Genes related to Cervical Adenocarcinoma (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	30.37	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14501820 18156982 18202755 (more) 16462152 19762530 11499840 9038270 10202666 15041997
2	KRT7	Keratin 7	Protein Coding	29.39	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14632574 19762530
3	CDX2	Caudal Type Homeobox 2	Protein Coding	28.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14632574 18156982 19762530
4	KRT20	Keratin 20	Protein Coding	28.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18156982 19762530 14632574
5	ESR1	Estrogen Receptor 1	Protein Coding	26.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8319181 1457356 12647218 (more) 9028361 9635534 10202666 10727981 17354237
6	RASSF1	Ras Association Domain Family Member 1	Protein Coding	25.87	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17360030 12702579
7	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	24.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20524403 11248419 11499840 (more) 10202666 15041997
8	TP53	Tumor Protein P53	Protein Coding	22.07	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	LAMC2	Laminin Subunit Gamma 2	Protein Coding	21.92	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16343183
10	EBAG9	Estrogen Receptor Binding Site Associated, Antigen, 9	Protein Coding	21.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : DISEASES inferred (show sections)	17981616 11104614
11	ZNF582	Zinc Finger Protein 582	Protein Coding	21.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	20.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	20.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	20.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	VIL1	Villin 1	Protein Coding	20.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Cervical Adenocarcinoma

Sources

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Sources

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 35)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.86	CDKN1A EGFR ERBB2 LAMC2 PTGS2 TP53
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.76	CDKN1A CDKN2A EGFR ERBB2 TP53
3	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.53	CDKN1A CDKN2A EGFR ERBB2 ESR1 RASSF1
4	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.48	CDKN1A EGFR ERBB2 TP53
5	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.47	CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
6	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.37	CDKN1A EGFR ERBB2 TP53
7	Pathways in cancer ³⁷	12.33	CDKN1A CDKN2A EGFR ERBB2 ESR1 LAMC2
8	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.21	EGFR ERBB2 ESR1 PTGS2
9	MicroRNAs in cancer ³⁷	12.18	CDKN1A CDKN2A EGFR ERBB2 PTGS2 RASSF1
10	Proteoglycans in cancer ³⁷	12.13	CDKN1A EGFR ERBB2 ESR1 TP53
11	Colorectal Cancer Metastasis ⁶⁴	12.09	CDKN1A EGFR PTGS2 TP53
12	AKT Signaling Pathway ⁶⁷	12.05	CDKN1A EGFR ERBB2 TP53
13	Direct p53 effectors ¹	11.96	CDKN1A EGFR TP53
14	Hepatitis C ³⁷	11.96	CDKN1A EGFR TP53
15	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	11.93	EGFR ERBB2 TP53
16	Spinal Cord Injury ¹	11.91	EGFR PTGS2 TP53
17	DNA Damage Response (only ATM dependent) ¹	11.9	CDKN1A CDKN2A ERBB2 TP53
18	Interleukin-4 and 13 signaling ⁶⁶	11.88	CDKN1A PTGS2 TP53
19	Glioblastoma Multiforme ⁶⁴	11.87	CDKN1A CDKN2A EGFR TP53
20	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.85	EGFR ERBB2 ESR1
21	Senescence and Autophagy in Cancer ¹	11.84	CDKN1A CDKN2A TP53
22	HIF-1 signaling pathway ³⁷	11.81	CDKN1A EGFR ERBB2
23	Small cell lung cancer ³⁷	11.76	CDKN1A LAMC2 PTGS2 TP53
24	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.75	CDKN1A EGFR ERBB2 ESR1
25	Platinum drug resistance ³⁷	11.62	CDKN1A CDKN2A ERBB2 TP53
26	Association Between Physico-Chemical Features and Toxicity Associated Pathways ¹	11.61	CDKN1A EGFR ERBB2
27	Central carbon metabolism in cancer ³⁷	11.59	EGFR ERBB2 TP53
28	Hepatitis C and Hepatocellular Carcinoma ¹	11.46	CDKN1A PTGS2 TP53
29	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.41	CDKN1A CDKN2A EGFR TP53
30	Aryl Hydrocarbon Receptor ¹	11.35	CDKN1A EGFR ESR1 PTGS2
31	Signaling mediated by p38-alpha and p38-beta ¹	11.27	ESR1 PTGS2 TP53
32	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	11.03	CDKN1A CDKN2A TP53
33	Bladder cancer ³⁷ ¹	10.96	CDKN1A CDKN2A EGFR ERBB2 RASSF1 TP53
34	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.71	CDKN1A TP53
35	Transcriptional activation of cell cycle inhibitor p21 ⁶⁶ Show member pathways Transcriptional activation of p53 responsive genes ⁶⁶	10.51	CDKN1A TP53

Sources

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.02	CDKN1A EGFR ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.93	CDKN2A EBAG9 KRT20 TP53 VIL1
2	positive regulation of transcription, DNA-templated	GO:0045893	9.85	CDKN2A CDX2 EGFR ESR1 TP53
3	negative regulation of apoptotic process	GO:0043066	9.83	CDKN1A EGFR ERBB2 PTGS2 TP53
4	response to organic cyclic compound	GO:0014070	9.74	CDKN1A EGFR PTGS2
5	negative regulation of cell growth	GO:0030308	9.73	CDKN1A CDKN2A TP53
6	phosphatidylinositol phosphorylation	GO:0046854	9.69	EGFR ERBB2 ESR1
7	response to estradiol	GO:0032355	9.67	EGFR ESR1 PTGS2
8	negative regulation of phosphorylation	GO:0042326	9.58	CDKN1A CDKN2A
9	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.55	CDKN1A TP53
10	negative regulation of ERBB signaling pathway	GO:1901185	9.52	EGFR ERBB2
11	positive regulation of fibroblast proliferation	GO:0048146	9.5	CDKN1A EGFR ESR1
12	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.48	ESR1 TP53
13	cell cycle arrest	GO:0007050	9.46	CDKN1A CDKN2A RASSF1 TP53
14	cellular response to epidermal growth factor stimulus	GO:0071364	9.43	EGFR ERBB2 VIL1
15	signal transduction by p53 class mediator	GO:0072331	9.4	CDKN1A TP53
16	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.37	CDKN2A ERBB2
17	Ras protein signal transduction	GO:0007265	9.26	CDKN1A CDKN2A RASSF1 TP53
18	replicative senescence	GO:0090399	8.8	CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.71	EGFR ESR1 PTGS2 TP53
2	protein phosphatase binding	GO:0019903	9.43	EGFR ERBB2 TP53
3	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.37	CDKN1A CDKN2A
4	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.33	EGFR ERBB2 ESR1
5	obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity	GO:0004716	9.32	EGFR ERBB2
6	protein kinase binding	GO:0019901	9.02	CDKN1A CDKN2A EGFR ESR1 TP53
7	nitric-oxide synthase regulator activity	GO:0030235	8.96	EGFR ESR1

Sources

Sources for Cervical Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia